Meta-Analysis
Copyright ©The Author(s) 2017.
World J Meta-Anal. Oct 26, 2017; 5(5): 124-131
Published online Oct 26, 2017. doi: 10.13105/wjma.v5.i5.124
Table 1 Summary of included studies
Study/yrCountryPatients No. (intervention/control)Mean age (intervention/control)Gender (male/female)Participants
Luo/2008China23/2337.2/36.527/19Aged 18 to 70 yr, with mild-to-moderate CD
Lazzerini/2013Italy28/2614.0/15.032/22Aged 2 to 18 yr with active CD
Mansfield/2007United Kingdom23/2841.5/41.321/30Aged 18 to 75 yr with moderately severe CD
33/2837.5/41.333/29
Table 2 Summary of included studies
Study/yrInterventionControlRemission (intervention/control)Response (intervention/control)Adverse effects (intervention/control)
Luo/2008Thalidomide100 mg/dSASP6/515/1310/9
4 g/d
Lazzerini/2013Thalidomide 50, 100 and 150 mg/dUnknown3/135/5Unknown/1
Mansfield/2007lenalidomide 25 mg ⁄d,Unknown2/74/410/18
lenalidomide 5 mg ⁄d10/76/412/10